Pooled resistance analysis in HCV genotype 1-6 infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials

Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, et al. Pooled resistance analysis in HCV genotype 1-6 infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. Antimicrob Agents Chemother. 2018;62(10):pii: e01249-18.

Publication Type:

Journal Article

Authors:

Krishnan, Preethi; Pilot-Matias, Tami; Schnell, Gretja; Tripathi, Rakesh; Ng, Teresa I.; Reisch, Thomas; Beyer, Jill; Dekhtyar, Tatyana; Irvin, Michelle; Xie, Wangang; Larsen, Lois; Mensa, Federico J.; Collins, Christine

Source:

Antimicrob Agents Chemother, Volume 62, Issue 10, p.pii: e01249-18 (2018)

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/30061289

Export Citation:
RIS Format
Top